Enzon Pharmaceuticals Stock Gross Profit
Enzon Pharmaceuticals fundamentals help investors to digest information that contributes to Enzon Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Enzon OTC Stock. The fundamental analysis module provides a way to measure Enzon Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Enzon Pharmaceuticals otc stock.
Enzon |
Enzon Pharmaceuticals OTC Stock Gross Profit Analysis
Enzon Pharmaceuticals' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current Enzon Pharmaceuticals Gross Profit | 701 K |
Most of Enzon Pharmaceuticals' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Enzon Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
CompetitionAccording to the company disclosure, Enzon Pharmaceuticals reported 701 K of gross profit. This is 99.97% lower than that of the Biotechnology sector and 99.93% lower than that of the Health Care industry. The gross profit for all United States stocks is 100.0% higher than that of the company.
Enzon Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Enzon Pharmaceuticals' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Enzon Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Enzon Pharmaceuticals by comparing valuation metrics of similar companies.Enzon Pharmaceuticals is currently under evaluation in gross profit category among its peers.
Enzon Fundamentals
| Return On Equity | -0.016 | ||||
| Return On Asset | -0.0138 | ||||
| Operating Margin | (36.28) % | ||||
| Current Valuation | 17.63 M | ||||
| Shares Outstanding | 74.21 M | ||||
| Shares Owned By Insiders | 10.70 % | ||||
| Shares Owned By Institutions | 48.58 % | ||||
| Number Of Shares Shorted | 259.38 K | ||||
| Price To Earning | 1.52 X | ||||
| Price To Book | 7.41 X | ||||
| Price To Sales | 669.36 X | ||||
| Revenue | 701 K | ||||
| Gross Profit | 701 K | ||||
| EBITDA | (469 K) | ||||
| Net Income | (469 K) | ||||
| Cash And Equivalents | 46.79 M | ||||
| Cash Per Share | 0.63 X | ||||
| Debt To Equity | 1.46 % | ||||
| Current Ratio | 125.26 X | ||||
| Book Value Per Share | 0.04 X | ||||
| Cash Flow From Operations | (501 K) | ||||
| Short Ratio | 1.71 X | ||||
| Earnings Per Share | (0.04) X | ||||
| Target Price | 14.0 | ||||
| Beta | 0.17 | ||||
| Market Capitalization | 19.72 M | ||||
| Total Asset | 47.75 M | ||||
| Retained Earnings | (75.61 M) | ||||
| Working Capital | 6.98 M | ||||
| Current Asset | 11.78 M | ||||
| Current Liabilities | 4.8 M | ||||
| Z Score | -1.4 | ||||
| Annual Yield | 0.65 % | ||||
| Net Asset | 47.75 M |
Pair Trading with Enzon Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enzon Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enzon Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Prologis could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Prologis when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Prologis - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Prologis to buy it.
The correlation of Prologis is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Prologis moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Prologis moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Prologis can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in nation. Note that the Enzon Pharmaceuticals information on this page should be used as a complementary analysis to other Enzon Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Enzon OTC Stock
If you are still planning to invest in Enzon Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Enzon Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |